TY - JOUR
T1 - Evaluating the Effectiveness of Hypertension Treatment in Delaying/Slowing the Progression of Chronic Kidney Disease in Adults Aged 18 Years and Above with Impaired Glucose Regulation: A Systematic Review Protocol
AU - Jadhakhan, Ferozkhan
AU - Safi, Ayaz
AU - Gai, Basiru
AU - Hossain, Muhammad
AU - Alkhatib, Ahmad
PY - 2025/12/11
Y1 - 2025/12/11
N2 - Introduction: Antihypertensive drugs effectively
reduce chronic kidney disease (CKD) progression, yet research into their
effectiveness for individuals with impaired glucose regulation (IGR) is
limited. IGR, which refers to intermediate hyperglycaemia, including
impaired fasting glucose and impaired glucose tolerance, represents a
high-risk metabolic state associated with both hypertension and
accelerated CKD progression. This systematic review evaluates the
effectiveness of hypertension treatment in delaying CKD progression in
individuals with IGR and aims to provide insights into optimal
drug-based treatments for this population.
Methods/Design: The electronic databases CINAHL,
EMBASE, MEDLINE, Web of Science, PubMed, Zetoc, Scopus, Cochrane Central
Register of Clinical Trials, and grey literature will be searched for
relevant studies from inception to 30th November 2025. Two
independent reviewers will screen results, extract data, select studies
for inclusion, and assess quality. Inclusion criteria encompass RCTs and
non-randomised studies involving adults with IGR and hypertension,
using CKD markers like estimated glomerular filtration rate, albumin
creatinine ratio, protein creatinine ratio, serum creatinine, and
creatinine clearance levels. The authors will estimate between-group and
within-group differences, extracting effect measures such as relative
risk, hazard ratio, or pre- and post-intervention means and SD, with 95%
CIs. If applicable, study results will be pooled for a meta-analysis;
high heterogeneity will prompt a narrative synthesis. Evidence quality
and risk of bias will be evaluated using the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) and Risk of Bias in
Non-randomised Studies of Interventions (ROBINS-I), respectively. This
systematic review protocol is registered with PROSPERO (CRD42024529193).
Conclusion: Current evidence supports
antihypertensive drugs in slowing CKD progression, but research on
individuals with IGR is limited. This review explores effective
drug-based treatment strategies for adults with CKD and IGR, enhancing
clinical practice and patient outcomes.
AB - Introduction: Antihypertensive drugs effectively
reduce chronic kidney disease (CKD) progression, yet research into their
effectiveness for individuals with impaired glucose regulation (IGR) is
limited. IGR, which refers to intermediate hyperglycaemia, including
impaired fasting glucose and impaired glucose tolerance, represents a
high-risk metabolic state associated with both hypertension and
accelerated CKD progression. This systematic review evaluates the
effectiveness of hypertension treatment in delaying CKD progression in
individuals with IGR and aims to provide insights into optimal
drug-based treatments for this population.
Methods/Design: The electronic databases CINAHL,
EMBASE, MEDLINE, Web of Science, PubMed, Zetoc, Scopus, Cochrane Central
Register of Clinical Trials, and grey literature will be searched for
relevant studies from inception to 30th November 2025. Two
independent reviewers will screen results, extract data, select studies
for inclusion, and assess quality. Inclusion criteria encompass RCTs and
non-randomised studies involving adults with IGR and hypertension,
using CKD markers like estimated glomerular filtration rate, albumin
creatinine ratio, protein creatinine ratio, serum creatinine, and
creatinine clearance levels. The authors will estimate between-group and
within-group differences, extracting effect measures such as relative
risk, hazard ratio, or pre- and post-intervention means and SD, with 95%
CIs. If applicable, study results will be pooled for a meta-analysis;
high heterogeneity will prompt a narrative synthesis. Evidence quality
and risk of bias will be evaluated using the Grading of Recommendations
Assessment, Development, and Evaluation (GRADE) and Risk of Bias in
Non-randomised Studies of Interventions (ROBINS-I), respectively. This
systematic review protocol is registered with PROSPERO (CRD42024529193).
Conclusion: Current evidence supports
antihypertensive drugs in slowing CKD progression, but research on
individuals with IGR is limited. This review explores effective
drug-based treatment strategies for adults with CKD and IGR, enhancing
clinical practice and patient outcomes.
KW - Impaired glucose tolerance
KW - chronic kidney disease
KW - hypertension
UR - https://www.open-access.bcu.ac.uk/16772/
U2 - 10.33590/emj/BAOK8956
DO - 10.33590/emj/BAOK8956
M3 - Review article
SN - 2054-6181
VL - 10
SP - 65
EP - 75
JO - European Journal of Diabetes
JF - European Journal of Diabetes
IS - 4
M1 - 10
ER -